Ironwood Pharmaceuticals | IRWD - Interest Expense On Debt


Ironwood Pharmaceuticals reported $8.74M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amarin USD 3K 5K Dec/2024
Ardelyx USD 5.6M 160K Mar/2026
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
Charles River Laboratories USD 26.74M 2.97M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Incyte USD 569K 13K Mar/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Pacira USD 3.7M 193K Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Takeda JPY 43.65B 79.98B Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025